{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:29:55Z","timestamp":1790695795830,"version":"4.1.0"},"reference-count":58,"publisher":"American Association for Cancer Research (AACR)","issue":"2","license":[{"start":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T00:00:00Z","timestamp":1644537600000},"content-version":"vor","delay-in-days":142,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013790","name":"Brain Research UK","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013790","id-type":"DOI","asserted-by":"crossref"}]},{"name":"DIPG Collaborative"},{"DOI":"10.13039\/501100001273","name":"CHILDREN with CANCER UK","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001273","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Abbie's Army"},{"name":"Lucas' Legacy"},{"name":"Lyla Nsouli Foundation"},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Somatic mutations in ACVR1 are found in a quarter of children with diffuse intrinsic pontine glioma (DIPG), but there are no ACVR1 inhibitors licensed for the disease. Using an artificial intelligence\u2013based platform to search for approved compounds for ACVR1-mutant DIPG, the combination of vandetanib and everolimus was identified as a possible therapeutic approach. Vandetanib, an inhibitor of VEGFR\/RET\/EGFR, was found to target ACVR1 (Kd = 150 nmol\/L) and reduce DIPG cell viability in vitro but has limited ability to cross the blood\u2013brain barrier. In addition to mTOR, everolimus inhibited ABCG2 (BCRP) and ABCB1 (P-gp) transporters and was synergistic in DIPG cells when combined with vandetanib in vitro. This combination was well tolerated in vivo and significantly extended survival and reduced tumor burden in an orthotopic ACVR1-mutant patient-derived DIPG xenograft model. Four patients with ACVR1-mutant DIPG were treated with vandetanib plus an mTOR inhibitor, informing the dosing and toxicity profile of this combination for future clinical studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Twenty-five percent of patients with the incurable brainstem tumor DIPG harbor somatic activating mutations in ACVR1, but there are no approved drugs targeting the receptor. Using artificial intelligence, we identify and validate, both experimentally and clinically, the novel combination of vandetanib and everolimus in these children based on both signaling and pharmacokinetic synergies.<\/jats:p>\n                    <jats:p>This article is highlighted in the In This Issue feature, p. 275<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2159-8290.cd-20-1201","type":"journal-article","created":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T20:25:33Z","timestamp":1632342333000},"page":"416-431","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Repurposing Vandetanib plus Everolimus for the Treatment of\n                    <i>ACVR1<\/i>\n                    -Mutant Diffuse Intrinsic Pontine Glioma"],"prefix":"10.1158","volume":"12","author":[{"given":"Diana M.","family":"Carvalho","sequence":"first","affiliation":[{"name":"1Division of Molecular Pathology, Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7813-041X","authenticated-orcid":false,"given":"Peter J.","family":"Richardson","sequence":"additional","affiliation":[{"name":"2BenevolentAI, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagore","family":"Olaciregui","sequence":"additional","affiliation":[{"name":"3Laboratory of Molecular Oncology, Hospital Sant Joan de D\u00e9u, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3977-7020","authenticated-orcid":false,"given":"Reda","family":"Stankunaite","sequence":"additional","affiliation":[{"name":"4Molecular Diagnostics, Royal Marsden Hospital NHS Trust, Sutton, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9630-3676","authenticated-orcid":false,"given":"Cinzia","family":"Lavarino","sequence":"additional","affiliation":[{"name":"3Laboratory of Molecular Oncology, Hospital Sant Joan de D\u00e9u, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Molinari","sequence":"additional","affiliation":[{"name":"1Division of Molecular Pathology, Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8660-9938","authenticated-orcid":false,"given":"Elizabeth A.","family":"Corley","sequence":"additional","affiliation":[{"name":"5Children & Young People's Unit, Royal Marsden Hospital NHS Trust, Sutton, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P.","family":"Smith","sequence":"additional","affiliation":[{"name":"2BenevolentAI, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0025-8872","authenticated-orcid":false,"given":"Ruth","family":"Ruddle","sequence":"additional","affiliation":[{"name":"6Division of Cancer Therapeutics, Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Donovan","sequence":"additional","affiliation":[{"name":"6Division of Cancer Therapeutics, Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akos","family":"Pal","sequence":"additional","affiliation":[{"name":"6Division of Cancer Therapeutics, Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence I.","family":"Raynaud","sequence":"additional","affiliation":[{"name":"6Division of Cancer Therapeutics, Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6017-8503","authenticated-orcid":false,"given":"Sara","family":"Temelso","sequence":"additional","affiliation":[{"name":"1Division of Molecular Pathology, Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Mackay","sequence":"additional","affiliation":[{"name":"1Division of Molecular Pathology, Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5859-1064","authenticated-orcid":false,"given":"John P.","family":"Overington","sequence":"additional","affiliation":[{"name":"7Medicines Discovery Catapult, Alderley Edge, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Phelan","sequence":"additional","affiliation":[{"name":"2BenevolentAI, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sheppard","sequence":"additional","affiliation":[{"name":"2BenevolentAI, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Mackinnon","sequence":"additional","affiliation":[{"name":"5Children & Young People's Unit, Royal Marsden Hospital NHS Trust, Sutton, United Kingdom."},{"name":"8Atkinson Morley Regional Neuroscience Centre, St George's Hospital NHS Trust, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassel","family":"Zebian","sequence":"additional","affiliation":[{"name":"9Department of Neurosurgery, Kings College Hospital NHS Trust, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safa","family":"Al-Sarraj","sequence":"additional","affiliation":[{"name":"10Department of Clinical Neuropathology, Kings College Hospital NHS Trust, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9715-1849","authenticated-orcid":false,"given":"Ashirwad","family":"Merve","sequence":"additional","affiliation":[{"name":"11Institute of Neurology, University College London Hospitals, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Pryce","sequence":"additional","affiliation":[{"name":"12South West London Pathology, St George's Hospital NHS Trust, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4773-3001","authenticated-orcid":false,"given":"Jacques","family":"Grill","sequence":"additional","affiliation":[{"name":"13Department of Pediatric and Adolescent Oncology and INSERM Unit U891, Team \u201cGenomics and Oncogenesis of Pediatric Brain Tumors,\u201d Gustave Roussy and University Paris-Saclay, Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2901-0742","authenticated-orcid":false,"given":"Michael","family":"Hubank","sequence":"additional","affiliation":[{"name":"4Molecular Diagnostics, Royal Marsden Hospital NHS Trust, Sutton, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7102-3283","authenticated-orcid":false,"given":"Ofelia","family":"Cruz","sequence":"additional","affiliation":[{"name":"14Paediatric Oncology, Neuro-Oncology Unit, Hospital Sant Joan de D\u00e9u, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Morales La Madrid","sequence":"additional","affiliation":[{"name":"14Paediatric Oncology, Neuro-Oncology Unit, Hospital Sant Joan de D\u00e9u, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Mueller","sequence":"additional","affiliation":[{"name":"15University Children's Hospital, Zurich, Switzerland."},{"name":"16University of California, San Francisco, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8485-426X","authenticated-orcid":false,"given":"Angel M.","family":"Carcaboso","sequence":"additional","affiliation":[{"name":"3Laboratory of Molecular Oncology, Hospital Sant Joan de D\u00e9u, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3094-3758","authenticated-orcid":false,"given":"Fernando","family":"Carceller","sequence":"additional","affiliation":[{"name":"5Children & Young People's Unit, Royal Marsden Hospital NHS Trust, Sutton, United Kingdom."},{"name":"17Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Jones","sequence":"additional","affiliation":[{"name":"1Division of Molecular Pathology, Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2021,9,22]]},"reference":[{"key":"2025120906412983300_bib1","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s11060-017-2372-5","article-title":"The international diffuse intrinsic pontine glioma registry: an infrastructure to accelerate collaborative research for an orphan disease","volume":"132","author":"Baugh","year":"2017","journal-title":"J Neurooncol"},{"key":"2025120906412983300_bib2","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nrclinonc.2012.87","article-title":"Paediatric and adult malignant glioma: close relatives or distant cousins?","volume":"9","author":"Jones","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"2025120906412983300_bib3","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11060-016-2363-y","article-title":"Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease","volume":"132","author":"Veldhuijzen van Zanten","year":"2017","journal-title":"J Neurooncol"},{"key":"2025120906412983300_bib4","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/neuonc\/nox107","article-title":"Contemporary survival endpoints: an International Diffuse Intrinsic Pontine Glioma Registry study","volume":"19","author":"Cooney","year":"2017","journal-title":"Neuro Oncol"},{"key":"2025120906412983300_bib5","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature10833","article-title":"Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma","volume":"482","author":"Schwartzentruber","year":"2012","journal-title":"Nature"},{"key":"2025120906412983300_bib6","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/ng.1102","article-title":"Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas","volume":"44","author":"Wu","year":"2012","journal-title":"Nat Genet"},{"key":"2025120906412983300_bib7","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/ng.2936","article-title":"Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations","volume":"46","author":"Buczkowicz","year":"2014","journal-title":"Nat Genet"},{"key":"2025120906412983300_bib8","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/ng.2950","article-title":"Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma","volume":"46","author":"Fontebasso","year":"2014","journal-title":"Nat Genet"},{"key":"2025120906412983300_bib9","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/ng.2925","article-title":"Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma","volume":"46","author":"Taylor","year":"2014","journal-title":"Nat Genet"},{"key":"2025120906412983300_bib10","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/ng.2938","article-title":"The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma","volume":"46","author":"Wu","year":"2014","journal-title":"Nat Genet"},{"key":"2025120906412983300_bib11","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1158\/0008-5472.CAN-14-1298","article-title":"ACVR1 mutations in DIPG: lessons learned from FOP","volume":"74","author":"Taylor","year":"2014","journal-title":"Cancer Res"},{"key":"2025120906412983300_bib12","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s42003-019-0420-8","article-title":"ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma","volume":"2","author":"Carvalho","year":"2019","journal-title":"Commun Biol"},{"key":"2025120906412983300_bib13","doi-asserted-by":"crossref","first-page":"303ra137","DOI":"10.1126\/scitranslmed.aac4358","article-title":"ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A","volume":"7","author":"Hatsell","year":"2015","journal-title":"Sci Transl Med"},{"key":"2025120906412983300_bib14","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41467-019-08823-9","article-title":"ACVR1 R206H cooperates with H3.1K27M in promoting diffuse intrinsic pontine glioma pathogenesis","volume":"10","author":"Hoeman","year":"2019","journal-title":"Nat Commun"},{"key":"2025120906412983300_bib15","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/nm.3855","article-title":"Functionally defined therapeutic targets in diffuse intrinsic pontine glioma","volume":"21","author":"Grasso","year":"2015","journal-title":"Nat Med"},{"key":"2025120906412983300_bib16","doi-asserted-by":"crossref","first-page":"eaaw0064","DOI":"10.1126\/scitranslmed.aaw0064","article-title":"Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening","volume":"11","author":"Lin","year":"2019","journal-title":"Sci Transl Med"},{"key":"2025120906412983300_bib17","doi-asserted-by":"crossref","first-page":"e0118926","DOI":"10.1371\/journal.pone.0118926","article-title":"A high-throughput in vitro drug screen in a genetically engineered mouse model of diffuse intrinsic pontine glioma identifies BMS-754807 as a promising therapeutic agent","volume":"10","author":"Halvorson","year":"2015","journal-title":"PLoS One"},{"key":"2025120906412983300_bib18","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/neuonc\/noz057","article-title":"DECIPHER pooled shRNA library screen identifies PP2A and FGFR signaling as potential therapeutic targets for diffuse intrinsic pontine gliomas","volume":"21","author":"Schramm","year":"2019","journal-title":"Neuro Oncol"},{"key":"2025120906412983300_bib19","article-title":"Drug screening linked to molecular profiling identifies novel dependencies in patient-derived primary cultures of paediatric high grade glioma and DIPG","author":"Carvalho","year":"2020","journal-title":"bioRxiv"},{"key":"2025120906412983300_bib20","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1080\/17460441.2019.1637414","article-title":"Transforming cancer drug discovery with Big Data and AI","volume":"14","author":"Workman","year":"2019","journal-title":"Expert Opin Drug Discov"},{"key":"2025120906412983300_bib21","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","article-title":"Baricitinib as potential treatment for 2019-nCoV acute respiratory disease","volume":"395","author":"Richardson","year":"2020","journal-title":"Lancet"},{"key":"2025120906412983300_bib22","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1473-3099(20)30270-X","article-title":"Baricitinib for COVID-19: a suitable treatment? Authors' reply","volume":"20","author":"Richardson","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2025120906412983300_bib23","doi-asserted-by":"crossref","first-page":"e12697","DOI":"10.15252\/emmm.202012697","article-title":"Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients","volume":"12","author":"Stebbing","year":"2020","journal-title":"EMBO Mol Med"},{"key":"2025120906412983300_bib24","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1473-3099(20)30132-8","article-title":"COVID-19: combining antiviral and anti-inflammatory treatments","volume":"20","author":"Stebbing","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2025120906412983300_bib25","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with Covid-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N Engl J Med"},{"key":"2025120906412983300_bib26","doi-asserted-by":"crossref","first-page":"18250","DOI":"10.1038\/s41598-020-74922-z","article-title":"Preclinical validation of therapeutic targets predicted by tensor factorization on heterogeneous graphs","volume":"10","author":"Paliwal","year":"2020","journal-title":"Sci Rep"},{"key":"2025120906412983300_bib27","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2169\/internalmedicine.1072-18","article-title":"A low crizotinib concentration in the cerebrospinal fluid causes ineffective treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer with carcinomatous meningitis","volume":"58","author":"Okimoto","year":"2019","journal-title":"Intern Med"},{"key":"2025120906412983300_bib28","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1158\/1078-0432.CCR-13-0306","article-title":"Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma","volume":"19","author":"Broniscer","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2025120906412983300_bib29","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/neuonc\/nou330","article-title":"Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma","volume":"17","author":"Truffaux","year":"2015","journal-title":"Neuro Oncol"},{"key":"2025120906412983300_bib30","doi-asserted-by":"crossref","first-page":"7900","DOI":"10.1021\/jm501177w","article-title":"Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants","volume":"57","author":"Mohedas","year":"2014","journal-title":"J Med Chem"},{"key":"2025120906412983300_bib31","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nbt1068","article-title":"A small molecule-kinase interaction map for clinical kinase inhibitors","volume":"23","author":"Fabian","year":"2005","journal-title":"Nat Biotechnol"},{"key":"2025120906412983300_bib32","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1200\/JCO.2010.30.3545","article-title":"Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma","volume":"28","author":"Broniscer","year":"2010","journal-title":"J Clin Oncol"},{"key":"2025120906412983300_bib33","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.lungcan.2015.04.004","article-title":"Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases","volume":"89","author":"Subbiah","year":"2015","journal-title":"Lung Cancer"},{"key":"2025120906412983300_bib34","doi-asserted-by":"crossref","first-page":"9035","DOI":"10.1200\/JCO.2018.36.15_suppl.9035","article-title":"Multi-kinase RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with RET rearranged non-small cell lung cancer","volume":"36","author":"Subbiah","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025120906412983300_bib35","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1097\/JTO.0b013e31828d08ae","article-title":"Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial","volume":"8","author":"Tsao","year":"2013","journal-title":"J Thorac Oncol"},{"key":"2025120906412983300_bib36","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1093\/annonc\/mdu269","article-title":"EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer","volume":"25","author":"Heymach","year":"2014","journal-title":"Ann Oncol"},{"key":"2025120906412983300_bib37","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ccell.2017.08.017","article-title":"Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma","volume":"32","author":"Mackay","year":"2017","journal-title":"Cancer Cell"},{"key":"2025120906412983300_bib38","doi-asserted-by":"crossref","first-page":"i54","DOI":"10.1093\/neuonc\/noy059.122","article-title":"DIPG-29. Preclinical efficacy of combined ACVR1 and PI3K\/mTOR inhibition in diffuse intrinsic pontine glioma (DIPG)","volume":"20","author":"Carvalho","year":"2018","journal-title":"Neuro Oncol"},{"key":"2025120906412983300_bib39","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1210\/me.2006-0071","article-title":"Mammalian target of rapamycin regulates the growth of mammary epithelial cells through the inhibitor of deoxyribonucleic acid binding Id1 and their functional differentiation through Id2","volume":"20","author":"Jankiewicz","year":"2006","journal-title":"Mol Endocrinol"},{"key":"2025120906412983300_bib40","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00280-009-1039-0","article-title":"Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences","volume":"65","author":"Azzariti","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025120906412983300_bib41","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ijpharm.2012.05.028","article-title":"Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp\/Abcb1) and breast cancer resistance protein (Bcrp1\/Abcg2) mediated efflux with m-TOR inhibitors","volume":"434","author":"Minocha","year":"2012","journal-title":"Int J Pharm"},{"key":"2025120906412983300_bib42","doi-asserted-by":"crossref","first-page":"100079","DOI":"10.1016\/j.esmoop.2021.100079","article-title":"Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study","volume":"6","author":"Cascone","year":"2021","journal-title":"ESMO Open"},{"key":"2025120906412983300_bib43","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2017.75.9308","article-title":"Clinical, radiologic, pathologic, and molecular characteristics of long-term survivors of diffuse intrinsic pontine glioma (DIPG): a collaborative report from the International and European Society for Pediatric Oncology DIPG Registries","volume":"36","author":"Hoffman","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025120906412983300_bib44","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s11060-011-0681-7","article-title":"Radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma","volume":"106","author":"Chassot","year":"2012","journal-title":"J Neurooncol"},{"key":"2025120906412983300_bib45","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11060-016-2151-8","article-title":"Pseudoprogression in children, adolescents and young adults with non-brainstem high grade glioma and diffuse intrinsic pontine glioma","volume":"129","author":"Carceller","year":"2016","journal-title":"J Neurooncol"},{"key":"2025120906412983300_bib46","first-page":"CD008218","article-title":"Anti-angiogenic therapy for high-grade glioma","volume":"11","author":"Ameratunga","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2025120906412983300_bib47","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1007\/s00280-013-2155-4","article-title":"Bevacizumab and central nervous system (CNS) hemorrhage","volume":"71","author":"Letarte","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025120906412983300_bib48","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1200\/JCO.2007.11.4017","article-title":"Phase I study of everolimus in pediatric patients with refractory solid tumors","volume":"25","author":"Fouladi","year":"2007","journal-title":"J Clin Oncol"},{"key":"2025120906412983300_bib49","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S1470-2045(10)70130-3","article-title":"Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis","volume":"11","author":"De Roock","year":"2010","journal-title":"Lancet Oncol"},{"key":"2025120906412983300_bib50","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1593\/neo.09814","article-title":"Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones","volume":"11","author":"Marchetti","year":"2009","journal-title":"Neoplasia"},{"key":"2025120906412983300_bib51","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/jnci\/djr523","article-title":"Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome","volume":"104","author":"Ihle","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"2025120906412983300_bib52","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/clpt.2013.34","article-title":"Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely: the ITC evidence-based position","volume":"94","author":"Kalvass","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"2025120906412983300_bib53","doi-asserted-by":"crossref","first-page":"5313","DOI":"10.1172\/JCI133310","article-title":"Everolimus improves the efficacy of dasatinib in PDGFR\u03b1-driven glioma","volume":"130","author":"Miklja","year":"2020","journal-title":"J Clin Invest"},{"key":"2025120906412983300_bib54","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1200\/JCO.2007.14.0988","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors","volume":"26","author":"O'Donnell","year":"2008","journal-title":"J Clin Oncol"},{"key":"2025120906412983300_bib55","first-page":"153","article-title":"Pediatric high-grade glioma: biologically and clinically in need of new thinking","volume":"19","author":"Jones","year":"2016","journal-title":"Neuro Oncol"},{"key":"2025120906412983300_bib56","doi-asserted-by":"crossref","first-page":"W488","DOI":"10.1093\/nar\/gkaa216","article-title":"SynergyFinder 2.0: visual analytics of multi-drug combination synergies","volume":"48","author":"Ianevski","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"2025120906412983300_bib57","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11060-016-2081-5","article-title":"Tumor DNA in cerebral spinal fluid reflects clinical course in a patient with melanoma leptomeningeal brain metastases","volume":"128","author":"Li","year":"2016","journal-title":"J Neurooncol"},{"key":"2025120906412983300_bib58","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s40478-018-0580-7","article-title":"CSF H3F3A K27M circulating tumor DNA copy number quantifies tumor growth and in vitro treatment response","volume":"6","author":"Stallard","year":"2018","journal-title":"Acta Neuropathol Commun"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/12\/2\/416\/3270769\/416.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/12\/2\/416\/3270769\/416.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:41:47Z","timestamp":1765280507000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/12\/2\/416\/678484\/Repurposing-Vandetanib-plus-Everolimus-for-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,22]]},"references-count":58,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,9,22]]},"published-print":{"date-parts":[[2022,2,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-20-1201","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2159-8290.c.6549445.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22540657.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.c.6549445","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22540657","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2159-8290.30834229","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.30834235","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.30834247","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.30834226","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.30834238","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.30834232","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.30834244","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.30834241","asserted-by":"object"}]},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,22]]}}}